An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic immune thrombocytopenic purpura (ITP), highlighting proactive strategies like ...

SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), ...

Immune thrombocytopenia (ITP) is a rare blood disorder in which the immune system mistakenly attacks and destroys platelets. Platelets are small blood cells that play a critical role in helping your ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window NEW ORLEANS -- ...

Please provide your email address to receive an email when new articles are posted on . Rilzabrutinib induced rapid and durable clinical activity in previously treated patients with immune ...

Please provide your email address to receive an email when new articles are posted on . Adding ianalumab to second-line eltrombopag prolonged time to treatment failure by more than 40%. Researchers ...

The European Medicines Agency (EMA) has recommended granting marketing authorization for rilzabrutinib (Wayrilz, Sanofi) to treat immune thrombocytopenia (ITP) in adults who are refractory to other ...

Primary immune thrombocytopenia (ITP) is an autoimmune condition where the body’s immune cells mistakenly attack platelets, the blood cells responsible for clotting, which can lead to life-threatening ...